September 3, 2015 | The Israeli biomedical company Mapi Pharma is making its third attempt at an initial public offering on NASDAQ. Mapi Pharma was submitted a prospectus to issue a $57.5 million offering at a currently undetermined company value. The underwriter for the offering is JMP Securities together with secondary underwriters Maxim and MLV. Mapi Pharma creates delayed release drugs and was founded in 2008.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments